Alvameline
Alternative Names: Alvameline maleate; Alvameline tartrate; LU 25109; LU 25109M; LU 25109TLatest Information Update: 18 May 2020
Price :
$50 *
At a glance
- Originator Lundbeck A/S
- Developer Forest Laboratories; Lundbeck A/S
- Class Nootropics
- Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M2 receptor antagonists; Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Urinary incontinence
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 30 Jan 2001 Discontinued-II for Urinary incontinence in USA (Unknown route)
- 27 Dec 2000 Phase-II clinical trials for Urinary incontinence in USA (Unknown route)